The potential of using TolDCs in therapeutic strategies for MS patients has been explored [42,86], and in two coordinated phase 1b trials, elevated IL-10 from peptide-specific T cells was associated with vitD3-TolDC therapy when loaded with a cocktail of myelin peptides (PLP, MOG, and MBP), producing an increase in the Tr1 frequency in MS patients [10,42,83]. Here, MOG is linked to myeloid sarcoma.